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Abstract. In the Democratic Republic of the Congo (DRC), artesunate-amodiaquine is first-line therapy for
falciparum malaria; little is known about the prevalence of molecular markers of parasite drug resistance. Across the
DRC, we genotyped 166 parasites in Plasmodium falciparum chloroquine resistance transporter (pfcrt) using polymerase
chain reaction (PCR) and sequencing. Of these parasites, 73 (44%) parasites were pure wild-type CVMNK, 55 (31%)
parasites were chloroquine-resistant CVIET, 35 (21.1%) parasites were mixed CVMNK and CVIET, and 3 parasites
were other genotypes. Ninety-two infections (55.4%) harbored the pfcrt K76T substitution that is highly correlated
with chloroquine failure. The amodiaquine-resistant SVMNT haplotype was absent. Geographically, pfcrt haplotypes
were not clearly clustered. Chloroquine accounted for 19.4% of antimalarial use, and amodiaquine accounted for
15.3% of antimalarial use; there were no associations between drug use and mutant haplotype prevalence. In the
DRC, our molecular survey indicates that resistance to chloroquine is substantial but that resistance to amodiaquine is
absent. These contrasting findings highlight the need for molecular surveillance of drug resistance to inform malaria
control policies.
Chloroquine (CQ)-resistant Plasmodium falciparum para-
sites are widespread and undermined prior efforts to control
falciparum malaria. Resistance is conferred by polymor-
phisms in the P. falciparum CQ resistance transporter
(PfCRT)1 encoded by the pfcrt gene. Clinically, the K76T
substitution elevates the risk of treatment failure sevenfold.2
Although pfcrt was originally associated with CQ susceptibil-
ity, a recent chemical genomic screen identified mutations in
pfcrt as key mediators of response to a diverse array of drugs,3
suggesting that the biological relevance of pfcrt extends far
beyond simply CQ.
Two observations suggest that CQ may be redeployed for
malaria control, despite widespread resistance. First, in
Malawi, CQ susceptibility returned over time after CQ use
was curtailed4 owing to the removal of selective pressure and
the reexpansion of CQ-susceptible parasites.5 Additionally,
even in the presence of the K76T mutation, the administra-
tion of higher doses of CQ can achieve cure rates similar to
the rates of artemether-lumefantrine.6 Because of these data,
interest persists in possibly redeploying CQ in certain epide-
miologic and clinical settings.
Central Africa harbors diverse pfcrt haplotypes that are
germane for clinical therapy. The Democratic Republic of
the Congo (DRC) adopted artesunate-amodiaquine (ASAQ)
as its first-line antimalarial in 2005, and neighboring Burundi,
Republic of the Congo, and South Sudan have also adopted
ASAQ. In the DRC, ASAQ is highly efficacious: the cure rate
of uncomplicated falciparum malaria was > 98% in Katanga
province in 2008 and 2009.7 Recent data confirm the
appearance in neighboring Tanzania8 and Angola9 of the pfcrt
haplotype SVMNT, which may confer resistance to
amodiaquine1,10 and herald failures of ASAQ.11 Additionally,
the haplotype SVIET has been reported from Kinshasa in
2000, although it is of unclear biological significance.12
To inform current and future guidelines on antimalarial use
in Central Africa, we conducted a cross-sectional survey of
pfcrt haplotypes in the DRC.
Parasites were obtained from respondents to the 2007
Demographic and Health Survey (DHS) in the DRC.13
Briefly, adults over 15 years old were selected for participa-
tion within 300 random population-representative clusters
identified across the DRC. Data about household antimalar-
ial use were collected by asking female respondents if chil-
dren under the age of 5 years in the household with fever
during the preceding 2 weeks had received an antimalar-
ial drug; data about drug use by individual respondents
who contributed parasite specimens were not collected. Ver-
bal informed consent for the collection of blood spots was
obtained from all survey participants in one of the five main
languages used in the DRC. The Ethics Committees of Macro
International and the School of Public Health of the Univer-
sity of Kinshasa approved the consent procedures, survey
administration, and blood sample collection. The Institutional
Review Board of the University of North Carolina approved
the testing of malaria parasites.
Finger-prick blood samples from the adult survey partici-
pants were stored on filter paper as dried blood spots and
used to make genomic DNA (gDNA). P. falciparum was
detected using real-time polymerase chain reaction (PCR).13
Of 8,838 adult respondents, 2,435 respondents harbored only
P. falciparum parasites. Of this subset, 180 P. falciparum
parasitemias were randomly selected for pfcrt genotyping.
Samples were genotyped at codons 72–76 by amplifying pfcrt
across the codons of interest and Sanger sequencing the prod-
uct. The 25 mL PCR reaction contained 12.5 mL HotStarTaq
Master Mix (Qiagen, Valencia, CA), 4 mMMgCl2, and 800 nM
each of primers CRTFwd (GGAAATGGCTCACGTTT-
AGG) and CRTRev (TGTGAGTTTCGGATGTTACAA-
AA; adapted from a previous study).14 PCR products were
bidirectionally sequenced using ABI BigDye Terminator
chemistry, and reads were aligned to National Center for Bio-
technology Information reference sequence XM_001348968
using Sequencher (v4.8; Gene Codes, Ann Arbor, MI). All
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sequences were manually inspected at the loci of interest. We
defined mixed alleles as those alleles at which a secondary peak
was ³ 10% of the height of the primary peak.
Of 180 randomly selected parasite isolates, 166 isolates were
successfully genotyped across pfcrt codons 72–76. Of these iso-
lates, the wild-type CVMNK haplotype was solely present in
73 (44.0%) isolates, the CQ-resistant haplotype CVIET was
solely present in 55 (33.1%) isolates, and 35 (21.1%) isolates
harbored parasites with both CVMNK and CVIET haplotypes.
Additionally, two isolates bore a CVMNT haplotype, and one
isolate had a CVMDK. Therefore, 92 of 166 samples that were
successfully genotyped (55.4%) harbored the K76T mutation
that most clearly confers CQ resistance.
The SVMNT haplotype reported previously from Angola
and Tanzania was absent, and the SVIET that had been
reported from Kinshasa was also absent. There were no novel
substitutions identified in the sequenced fragment of pfcrt.
Geographically, the most common wild-type (CVMNK) and
mutant (CVIET) haplotypes were widely distributed across the
DRC without apparent geographic clustering (Figure 1A). The
prevalence of the K76Tmutation was not significantly different
between 11 DRC provinces.
Of 790 DHS respondents with children under 5 years who
received antimalarials in the preceding 2 weeks for fever, the
most commonly administered antimalarials were quinine
(49.6%), CQ (19.4%), amodiaquine (15.3%), and sulfadoxine-
pyrimethamine (9.7%). On a provincial level, there were no
significant differences in antimalarial use (Figure 1B).
Overall, we report a higher prevalence of wild-type pfcrt
haplotypes than prior studies in the region: 44% of isolates in
our study harbored the CVMNK haplotype alone. In three stud-
ies in Kinshasa or neighboring Republic of the Congo, wild-type
CVMNK haplotype prevalence was 4–12%,15–17 and only 3%
of isolates collected in Luanda, Angola in 2007 harbored wild-
type pfcrt.9 We note that, consistent with these studies, preva-
lence of wild-type parasites was lower than the national average
in Kinshasa and Bas-Congo provinces (Figure 1A).
What might these data mean for CQ redeployment? Cur-
rently, ASAQ is effective therapy for malaria in the DRC, but
the recent reports of reduced efficacy of artemisinin therapies
for malaria in Asia highlight the need to continually evaluate
the efficacy of alternative drugs. The correlation between
prevailing K76T mutation frequency and the efficacy of CQ
is unknown. In Malawi, 25 mg/kg CQ were highly effective in
treating uncomplicated childhood malaria in a setting where
the prevalence of the K76T mutation was < 0.2%.18 More
surprisingly, in a Guinea-Bissau study in which 31% of para-
sites harbored K76T, 50 mg/kg CQ were 94% effective as
treatment of uncomplicated malaria.6 Given these data, it
seems plausible that a threshold of prevailing K76T frequency
may define locations where it is likely to be effective. Areas
with moderate but heterogeneous mutation prevalence, like
the DRC, can provide settings in which to test CQ efficacy
and its correlation with molecular markers of resistance.
Nonetheless, redeploying CQ in an area with parasites bear-
ing K76T mutations will promote the spread of resistant par-
asites and ultimately, reduce drug efficacy. For this reason,
clinical and molecular monitoring of drug resistance will be
critical if CQ is deployed in any limited setting.
Persistent CQ use for childhood fever may be sustaining
transmission of K76T-bearing parasites in the DRC. In
Malawi, the decrease in CQ use facilitated a return of CQ-
susceptible parasites, but in a meta-analysis of population-
level data from several other African countries, continued
CQ use was associated with the persistence of CQ resis-
tance.19 Although parasites bearing mutant pfcrt haplotypes
Figure 1. Provincial distributions of (A) pfcrt haplotypes and (B) antimalarial drug use for childhood fever.
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are believed to suffer an overall fitness disadvantage, it may be
counterbalanced in the presence of continued drug pressure by
increased infectivity to mosquitos.20 The K76T mutation may
be further sustained by the poor quality of CQ formulations in
the DRC,21 which may simultaneously fail to clear parasites
and promote gametocytogenesis. Until 2002, when failure rates
reached 45%,22 CQ was the first-line antimalarial for uncom-
plicated malaria; our study was conducted in 2007, and its
administration for 20% of treated childhood fevers may reflect
residual practice patterns, which have since abated.
Notably, no parasites in our study harbored the SVMNT
haplotype. This haplotype has been reported in Angola and
Tanzania, and it has been associated with resistance to
amodiaquine in a clinical study in Afghanistan10 and in vitro
experimentation.1 Our study was conducted only 2 years after
the adoption of ASAQ as first-line antimalarial in the DRC,
and respondents endorsed minimal use for childhood antima-
larial treatment of either amodiaquine (4.9%) or artesunate
(0.6%). Our data suggest that ASAQ may be a durable anti-
malarial, although ongoing surveillance is necessary.
Our study has several limitations. We sampled only 166 iso-
lates from a large country. Nevertheless, they were randomly
sampled from a nationally representative survey, and we
believe that they reflect DRC parasite populations in a less-
biased fashion than more local studies. Our genotyping
method may have missed minority variant subpopulations,
although we set a liberal cutoff for secondary peaks in chro-
matograms, all of which were scored manually. We have no
clinical efficacy data with which to correlate our molecular
data, and future studies are needed to understand the impact
of the pfcrt prevalence. Finally, the DHS did not collect data
on the recent use of antimalarials by the participants them-
selves. The pfcrt K76T mutation decreases susceptibility to
both CQ and amodiaquine; if participants had recently
received these antimalarials in the period before the survey,
they would be expected to inflate the reported mutant allele
frequencies above their true values.
Across the DRC, parasites bearing pfcrt haplotypes confer-
ring CQ resistance remain prevalent, perhaps owing to ongo-
ing CQ use for childhood fever. A pfcrt haplotype associated
with amodiaquine resistance was absent, suggesting that first-
line antimalarial ASAQ may be a durable therapy. Ongoing
population-level molecular surveillance may assist strategies
to redeploy CQ in select African settings.
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